Larry Biegelsen
Stock Analyst at Wells Fargo
(4.35)
# 433
Out of 4,745 analysts
295
Total ratings
61.71%
Success rate
12.69%
Average return
Main Sectors:
Stocks Rated by Larry Biegelsen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ISRG Intuitive Surgical | Maintains: Overweight | $630 → $687 | $584.05 | +17.63% | 19 | Jan 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $166 → $152 | $146.82 | +3.53% | 13 | Jan 23, 2025 | |
| BLCO Bausch + Lomb | Maintains: Overweight | $26 → $24 | $17.19 | +39.62% | 4 | Jan 16, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $42 → $40 | $32.48 | +23.15% | 9 | Jan 13, 2025 | |
| NARI Inari Medical | Downgrades: Equal-Weight | $65 → $80 | $79.74 | +0.33% | 6 | Jan 7, 2025 | |
| SYK Stryker | Maintains: Overweight | $405 → $427 | $394.31 | +8.29% | 14 | Dec 11, 2024 | |
| GKOS Glaukos | Maintains: Overweight | $145 → $153 | $160.22 | -4.51% | 12 | Dec 11, 2024 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $10 → $8 | $6.11 | +30.93% | 6 | Dec 11, 2024 | |
| DXCM DexCom | Maintains: Overweight | $90 → $94 | $88.75 | +5.92% | 9 | Dec 11, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $98 → $100 | $101.94 | -1.90% | 12 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $103 → $120 | $104.64 | +14.68% | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $190 → $275 | $274.06 | +0.34% | 14 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $118 | $97.70 | +20.78% | 16 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $106 → $98 | $90.19 | +8.66% | 17 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $187 → $198 | $188.47 | +5.06% | 10 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $96 | $88.67 | +8.27% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $117 | $110.81 | +5.59% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $80 | $68.99 | +15.96% | 15 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $94 → $105 | $88.96 | +18.03% | 8 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $44 → $40 | $32.45 | +23.27% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $36.50 | +50.68% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $40 | $26.33 | +51.92% | 17 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $14 | $5.16 | +171.32% | 11 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.1 → $1.6 | $0.99 | +62.35% | 3 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $49 | $26.05 | +88.10% | 2 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $241 → $236 | $180.98 | +30.40% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $136 | $125.03 | +8.77% | 21 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $70 | $92.84 | -24.60% | 7 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $270 | $243.45 | +10.91% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $97.50 | - | 2 | Nov 2, 2017 |
Intuitive Surgical
Jan 24, 2025
Maintains: Overweight
Price Target: $630 → $687
Current: $584.05
Upside: +17.63%
Johnson & Johnson
Jan 23, 2025
Maintains: Equal-Weight
Price Target: $166 → $152
Current: $146.82
Upside: +3.53%
Bausch + Lomb
Jan 16, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $17.19
Upside: +39.62%
RxSight
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $32.48
Upside: +23.15%
Inari Medical
Jan 7, 2025
Downgrades: Equal-Weight
Price Target: $65 → $80
Current: $79.74
Upside: +0.33%
Stryker
Dec 11, 2024
Maintains: Overweight
Price Target: $405 → $427
Current: $394.31
Upside: +8.29%
Glaukos
Dec 11, 2024
Maintains: Overweight
Price Target: $145 → $153
Current: $160.22
Upside: -4.51%
Pulmonx
Dec 11, 2024
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $6.11
Upside: +30.93%
DexCom
Dec 11, 2024
Maintains: Overweight
Price Target: $90 → $94
Current: $88.75
Upside: +5.92%
Boston Scientific
Dec 11, 2024
Maintains: Overweight
Price Target: $98 → $100
Current: $101.94
Upside: -1.90%
Dec 11, 2024
Upgrades: Overweight
Price Target: $103 → $120
Current: $104.64
Upside: +14.68%
Dec 11, 2024
Upgrades: Overweight
Price Target: $190 → $275
Current: $274.06
Upside: +0.34%
Dec 6, 2024
Maintains: Overweight
Price Target: $115 → $118
Current: $97.70
Upside: +20.78%
Nov 20, 2024
Maintains: Overweight
Price Target: $106 → $98
Current: $90.19
Upside: +8.66%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $187 → $198
Current: $188.47
Upside: +5.06%
Oct 31, 2024
Maintains: Overweight
Price Target: $95 → $96
Current: $88.67
Upside: +8.27%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $110 → $117
Current: $110.81
Upside: +5.59%
Sep 9, 2024
Maintains: Overweight
Price Target: $90 → $80
Current: $68.99
Upside: +15.96%
Aug 22, 2024
Maintains: Overweight
Price Target: $94 → $105
Current: $88.96
Upside: +18.03%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $44 → $40
Current: $32.45
Upside: +23.27%
Aug 2, 2024
Maintains: Overweight
Price Target: $50 → $55
Current: $36.50
Upside: +50.68%
Jul 26, 2024
Maintains: Overweight
Price Target: $42 → $40
Current: $26.33
Upside: +51.92%
Apr 8, 2024
Maintains: Equal-Weight
Price Target: $17 → $14
Current: $5.16
Upside: +171.32%
Mar 22, 2024
Maintains: Equal-Weight
Price Target: $2.1 → $1.6
Current: $0.99
Upside: +62.35%
Dec 5, 2023
Upgrades: Overweight
Price Target: $40 → $49
Current: $26.05
Upside: +88.10%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $241 → $236
Current: $180.98
Upside: +30.40%
Apr 5, 2023
Maintains: Overweight
Price Target: $140 → $136
Current: $125.03
Upside: +8.77%
May 11, 2022
Maintains: Overweight
Price Target: $80 → $70
Current: $92.84
Upside: -24.60%
Apr 8, 2020
Maintains: Overweight
Price Target: $279 → $270
Current: $243.45
Upside: +10.91%
Nov 2, 2017
Upgrades: Outperform
Price Target: n/a
Current: $97.50
Upside: -